Australia: The Regulatory and Reimbursement Environment
This article is the third in a three-part series that aims to provide sponsors with information about Australia as a highly attractive option for drug research and development. Australia offers a mature infrastructure and experienced, capable local resources, especially important given global geopolitical uncertainties. Here, we examine the clinical trial start-up processes, regulatory pathway, market access, pricing system, and pricing control, with particular emphasis on cell and gene therapy with a case study to illustrate.
Interested in more? Check out part 1 and part 2.
Related Insights
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Related Insights
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023